Hims & Hers Introduces Multi-Cancer Early Detection Testing to Expand Access to Proactive Preventive Care
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched…
Clarest Health Launches “Clarest at Home” to Improve Medication Continuity from Facility to Home
Clarest Health Launches “Clarest at Home,” Closing the Gap in Medication Management from Facility to Front Door Clarest Health, a leader in personalized medication management, announced the launch of Clarest at…
Nubeqa™ (Darolutamide) Secures Third Approval in China for Treatment of Advanced Prostate Cancer in Men
Nubeqa™ (Darolutamide) Gains Third Approval in China for Treatment of Advanced Prostate Cancer in Men The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi)…
Bristol Myers Squibb Launches “Change the Target. Change What’s Possible.” to Address Unmet Needs in Cardiovascular and Thromboembolic Care
Bristol Myers Squibb Launches “Change the Target. Change What’s Possible.” Campaign to Address Unmet Needs in Cardiovascular and Thromboembolic Care Bristol Myers Squibb announced today the launch of “Change the Target.…
Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained, Significant Weight Loss in Phase 2b Trial
Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained and Significant Weight Loss in Phase 2b Trial Pfizer Inc. today announced positive topline results from the Phase 2b VESPER-3 study investigating…
Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium
Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in…
FDA Accepts Exelixis’ NDA for Zanzalintinib Combo in Metastatic Colorectal Cancer
Exelixis Announces FDA Acceptance of New Drug Application for Zanzalintinib Combined with Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Exelixis, Inc. today announced that its New Drug Application (NDA) for…
Bio-Techne Launches Fully Defined Synthetic Solution to Expand 3D Stem Cell and Organoid Culture Portfolio
Bio-Techne Broadens 3D Stem Cell and Organoid Culture Offerings with a Fully Defined, Synthetic Matrix Alternative Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic…
Phase 3 Trial of Fezolinetant in Japan Reports Positive Topline Results for Menopausal Vasomotor Symptoms (VMS)
Phase 3 Trial of Fezolinetant in Japan Reports Positive Topline Results for Menopausal Vasomotor Symptoms (VMS) Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced topline…
EYLEA HD® 8 mg Data at Angiogenesis 2026 Highlight Robust Retinal Disease Profile
EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio…
ERLEADA® Shows 51% Lower Mortality vs Darolutamide in mCSPC (Real-World, 24-Month Analysis)
Real-World Head-to-Head Analysis Reveals 51% Lower Risk of Death in Metastatic Castration-Sensitive Prostate Cancer Patients Treated with ERLEADA® (Apalutamide) Compared to Darolutamide—Without Docetaxel—Over 24 Months Johnson & Johnson today announced new…
CagriSema Shows 1.91% HbA1c Drop, 14.2% Weight Loss in REIMAGINE 2 Trial
Novo Nordisk A/S: CagriSema Shows Superior HbA1c Reduction of 1.91% and 14.2% Weight Loss in Adults with Type 2 Diabetes in REIMAGINE 2 Trial Novo Nordisk today announced headline results…